RBC Capital analysts provided their outlook on Clarivate (NYSE:CLVT) ahead of the upcoming Q3/22 earnings, trimming their H2/22 and fiscal 2023 estimates to account for incremental FX headwinds, higher interest expense, and a more cautious view on transactional revenues, given the potential economic slowdown.
Accordingly, the analysts lowered their 2022/2023 EPS estimates to $0.80/$0.83, below the Street estimates of $0.85/ $0.95, and reduced their price target to $13 from $16.
Although the company lowered organic growth for Q3/22 to approximately 3%, the analysts believe the company should also de-risk organic growth expectations for Q4/22 and 2023 in light of the challenging macro environment.